CMS projects lower premiums and broad plan availability, but market exits, shifting quality performance, and mounting financial pressures suggest a more complicated reality. 

The outlook for Medicare Advantage in 2027 is raising some difficult questions. 

Health plans are exiting markets, restructuring benefits, and facing continued pressure to protect margins while maintaining quality and competitive coverage. 

Yet CMS's latest projections paint a seemingly different picture. 

Average Medicare Advantage premiums are expected to decline by 16.5%, and more than 99% of Medicare beneficiaries will continue to have access to at least one MA plan. 

On the surface, those numbers suggest stability. 

But for health plan leaders navigating rising medical costs, shifting quality performance, and increasingly difficult financial decisions, the reality is far more nuanced. 

How can the market look stable on paper while so many insurers are being forced to reconsider where and how they compete? 

The answer lies in what national averages don't reveal. 

Stability and Sustainability Aren't the Same Thing 

According to CMS, the average monthly Medicare Advantage premium is projected to decline from $14.37 in 2026 to $12.00 in 2027. 

Meanwhile, recent reporting from Becker's identifies 12 insurers exiting Medicare Advantage markets in 2027, including eight affiliated with health systems. 

Among those announcing exits or withdrawals from Medicare Advantage markets are: 

Established Blue Cross Blue Shield insurers: 

• Wellmark Blue Cross Blue Shield (Iowa and South Dakota) 

• Blue Cross Blue Shield of Mississippi / Patrius Health 

• Blue Cross Blue Shield of North Dakota 

Health system-affiliated insurers: 

• Braven Health 

• Christus Health Plan 

• Providence Health Plan 

• WellSense Health Plan 

• Memorial Hermann Health Plan 

• Mass Advantage (UMass Memorial Health) 

• Aspirus Health Plan 

• Sharp Health Plan 

And these changes extend beyond the organizations listed above. Major national insurers are also reducing their Medicare Advantage footprints in selected markets. 

These aren't just isolated market adjustments. They signal a broader reassessment of where, and under what conditions, Medicare Advantage participation remains financially sustainable. 

Broad access to Medicare Advantage doesn't necessarily mean every plan, provider network, or contractual arrangement is financially viable. 

For the organizations that remain, the pressure to manage medical costs, improve quality, and maintain competitive benefits isn't disappearing. 

In many cases, it's becoming more consequential. 

The 2027 Star Ratings Reinforce What's at Stake 

The latest Medicare Advantage Star Ratings add another dimension to the conversation. 

On October 8, CMS released the 2027 Star Ratings, revealing that approximately 37% of Medicare Advantage prescription drug contracts earned four stars or higher, down from approximately 44% in 2026. 

Although approximately 71% of MA-PD enrollees are currently in contracts rated four stars or higher, performance varies considerably across insurers. 

Some organizations have made significant gains. Others are contending with declines that could have financial implications beyond the immediate performance period. 

The 2027 ratings will influence 2028 quality bonus payments, reinforcing the connection between quality performance and long-term financial sustainability. 

But there's another consideration. 

By the time a quality rating reveals an unfavorable outcome, many opportunities to influence the underlying performance measures may have already passed. 

Consider a health plan struggling to close care gaps within a particular provider network.

The quality team may recognize that certain measures are falling behind. 

The network team may identify providers with consistently low engagement or underperformance. 

The finance team may be evaluating the implications of quality performance on future revenue. 

All three are examining different dimensions of the same challenge. 

The opportunity is to connect those perspectives before the performance period closes, not simply explain the results afterward. 

For health plans, improving quality isn't exclusively about achieving a higher rating. 

It's about understanding where performance is falling short, what's contributing to those gaps, and which interventions have the greatest potential to make a measurable difference. 

Rising Medical Costs Require More Than Retrospective Answers 

Medical economics leaders understand that rising utilization rarely tells the whole story.

An increase in emergency department visits may reflect access barriers, gaps in chronic disease management, changes in member acuity, or performance differences across provider groups. 

The cost impact may be visible in financial reporting. 

But the underlying drivers aren't always as obvious. 

And when those insights sit across disconnected systems or departments, opportunities to intervene can become harder to recognize. 

Imagine a health plan identifies an unexpected increase in emergency department utilization. 

A retrospective analysis may eventually show that medical expenses exceeded expectations for the quarter. 

Useful information, certainly. 

But what if the organization could identify that trend earlier? 

What if it could determine which attributed populations were contributing to the increase, investigate potential drivers, and identify interventions that might reduce avoidable utilization? 

The difference isn't simply having better data. It's actionability; being able to do something with that data while the opportunity still exists.  

That could mean engaging specific provider groups, addressing outstanding care gaps, evaluating chronic condition management, or examining patterns that suggest opportunities to improve care delivery. 

Not every unfavorable trend is preventable, and not every intervention will produce immediate savings. 

Earlier insight creates more opportunities to investigate, prioritize, and influence performance before outcomes are finalized. And for health plans operating under significant margin pressure, that distinction can translate into millions of dollars. 

Are Health Plans Measuring Performance or Managing It?

The developments surrounding 2027 raise an important question. 

Have healthcare organizations become better at reporting performance than actively influencing it? 

Most health plans have invested substantially in analytics, dashboards, and performance measurement. They can track medical loss ratios, evaluate quality metrics, monitor utilization, and identify underperforming contracts. 

But those capabilities don't automatically translate into better results. 

A dashboard can identify that a medical loss ratio is trending unfavorably but it doesn't necessarily explain which utilization patterns, provider relationships, or population-level factors are contributing to that trend. 

A quality report can highlight missed targets but it doesn't always reveal which open care gaps remain actionable or where intervention could have the greatest impact. 

And a contract performance report may identify financial underperformance without clearly connecting those results to the operational factors influencing them. 

Knowing where performance stands is important. Knowing why it's changing and what to do next is what creates the opportunity to improve it. 

For health plan executives, that means asking more connected questions: 

• Where are risks emerging? Which markets, contracts, provider groups, or member populations are contributing to unfavorable trends? 

• What's driving those changes? Is the issue utilization, quality performance, risk adjustment, membership shifts, or a combination of factors? 

• Where is the greatest opportunity to intervene? Which actions have meaningful clinical or financial potential, and which can still realistically influence outcomes? 

• How do we move from insight to execution? Are financial, clinical, quality, and network teams working from the same information and priorities? 

These questions cannot always be answered through isolated dashboards or retrospective reporting alone. 

They require connected intelligence across the functions that influence performance.

More importantly, they require an operational commitment to turning those insights into action. 

The Real Opportunity Isn't in Predicting Change. It's in Getting Ahead of It. 

Truthfully, the challenges emerging in 2027 aren't entirely new. 

Medical cost pressures, quality performance requirements, provider alignment, and the need for stronger financial visibility have been part of the industry conversation for years. 

What's changing is the tolerance for inefficiency. 

As organizations reassess market participation, benefits, and financial sustainability, the ability to identify and address performance challenges earlier becomes increasingly valuable. 

And that requires a shift in perspective. 

Rather than asking only what happened to medical costs, health plans need to understand what's driving them. 

Rather than simply measuring provider performance, they need to identify opportunities to improve it. 

Rather than waiting for unfavorable results to appear in quarterly reporting, they need greater visibility into the factors shaping those outcomes. 

At SpectraMedix, we believe that shift is essential to the future of healthcare performance management. Which is why our approach brings together a prospective approach to intelligence across quality, risk, utilization, financial performance, and provider relationships to help health plans identify opportunities for improvement and connect them to meaningful action. 

We know most plans don’t need another dashboard telling them something caused a problem after the window to fix it has closed. 

Many however do need the intelligence to detect and act on opportunities while there's still an opportunity to make a difference. 

The Bottom Line 

CMS's 2027 projections offer an important view of Medicare Advantage at the national level. But market exits, benefit restructuring, and shifting quality performance tell us that the financial and operational realities facing individual health plans are considerably more complex. 

And while national averages may suggest stability, sustainability will ultimately depend on the decisions and actions organizations take within their own markets, networks, and contracts. 

For health plan leaders, the question isn't simply how to navigate another year of change. 

It's whether they have the visibility, intelligence, and operational alignment to recognize emerging risks and opportunities early enough to influence the outcome. 

Because in an increasingly demanding Medicare Advantage market, knowing what happened isn't enough. The greater advantage belongs to organizations that know what to do next. 

Explore how SpectraMedix helps health plans turn intelligence into action. 

Sources and Further Reading 

1. CMS: Medicare Advantage and Medicare Prescription Drug Programs Expected to Remain Stable in 2027 — September 28, 2026 

2. CMS: 2027 Medicare Advantage and Part D Star Ratings — October 8, 2026 

3. Becker's: 12 Payers Exiting Medicare Advantage in 2027 — September 30, 2026 

4. Becker's: Medicare Advantage Looks Stable for 2027. Underneath, It's Shifting — October 1, 2026